RightHill Ventures

BrightEdge propels groundbreaking patient-centric solutions by investing in and supporting the most innovative startup companies to advance science, reduce disparities, and promote healthcare sustainability. BrightEdge is the innovation, impact investment, and venture capital arm of the American Cancer Society (ACS). Through our donor-funded ACS Impact Venture Fund (AIVF), we further ACS’s mission by investing in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate our vision of ending cancer as we know it, for everyone. About BrightEdge and The American Cancer Society BrightEdge is helping create a stream of alternate income to sustain the critical work being done across our pillars. Donations to BrightEdge become a sustainable source of financial support to the American Cancer Society, diversifying and modernizing the ACS’s income sources. Investment returns from the AIVF portfolio are both reinvested in AIVF to further support new and existing companies in the portfolio and additional proceeds are used to sustain ACS’s lifesaving programs in research, access, and health equity. BrightEdge investment decisions and innovation programming are guided by the mission priorities of ACS and seek to achieve mission-driven social impact through its proprietary Cancer Impact Investment FrameworkTM (CIIFTM). BrightEdge builds on the American Cancer Society’s commitment to funding and conducting cancer research and plays a key role in accelerating today’s most promising oncology-focused technologies. Our ability to translate scientific discoveries into accessible cures and solutions depends on investments in entrepreneurial for-profit companies that can validate, develop, and commercialize products and services at scale in the healthcare marketplace for people facing cancer. BrightEdge plays a unique role alongside traditional venture capital firms by addressing early-stage funding gaps, incubating high-impact companies, bringing system-level knowledge to companies at critical points in product development, and helping emerging companies access world-class intellectual and human capital as they grow. Learn how BrightEdge will help improve 1.5 million lives by investing in cancer-focused therapies and technologies in its most recent annual report and infographic.

When we founded the firm in 2007, our imaginations were on fire with the possibility of translating scientific discoveries to breakthrough medicines. Could we finally find cures for cancer? Would we be able to diagnose diseases before they even appear? How far could we go in restoring hope and quality of life to patients with incurable conditions? We dared to believe that nothing was impossible. To achieve what hadn’t been done before, we created a process that hadn’t been done before. By starting with big ideas and fostering collaboration among brilliant people with expertise in science, medicine, business and strategy, we set out to do more than fund startups – we aim to build sustainable, innovative companies that can transform the lives of patients. Discover Our Discovery effort is a collaborative and iterative process. We look for emerging fields of science and medicine where the time is right for us to bring transformative change to areas of unmet medical need. Working with leading scientific founders and expert advisors, we then develop a clear vision and strategy for a company with the patient front and center. With 12 years and over 50 companies worth of experience, we have created an industry-leading and differentiated approach to bring breakthrough science to patients. Launch Once a company concept has been refined and optimized through our Discovery process, we Launch the company with the necessary financial, technical and human resources to enable it to reach milestones critical for its growth and success. We become active members of the company’s leadership team, serving in interim roles to ensure the execution of the company’s R&D strategy, and to build a world-class team that shares the company’s scientific vision. Importantly, we work to establish a dynamic and innovative culture at launch where the growing team has a unified passion and commitment to make a difference in the lives of patients. Build Next, we Build on that foundation. We transition out of our interim roles and establish experienced and motivated management teams. As board members and domain experts, we work with these teams for as long as is needed to relentlessly execute on the strategy, bringing whatever resources are required from within the firm to deliver on our commitment to patients. An important element is the work we do to cultivate future partnerships and drive value creating transactions. Our companies also have access to our Beyond Great learning community, which provides peer-to-peer networking for leaders across the portfolio as well as tools and resources focused on shared elements of building successful and sustainable companies. Transform Our companies are now bringing products to patients – Transforming their lives, and the lives of their families. Third Rock portfolio companies have now launched 16 products. It is this that we are most proud of, as it means we are delivering on our mission of creating great companies that discover and develop products that make a difference for the patients we serve. Mission & Core Values Third Rock's mission is to be the preferred partner for entrepreneurs, investors, employees and industry to build great companies that discover and develop products that make a difference for the patients we serve. Integrity: always do the right thing Attitude: nothing is impossible Patients: making a difference through breakthroughs in medicine Partners: make them raving fans Organization: great people, great culture, great accomplishments Entrepreneurs: passionately innovate, found, build, have fun

Since 2006 we’ve backed Yale faculty doing cutting edge research on some of the world’s largest problems. With Yale as our largest investor, we’ve supported teams developing much-needed therapeutics, advanced tools and materials for industry, and critical interventions for a warming planet. Our thesis is that great people and great science lead to great impact. YALE AND NEW HAVEN We are primarily interested in companies with a Yale connection, typically technology developed at and licensed from Yale. We also invest in companies located in the greater New Haven area, and, in exceptional cases, non-Yale/non-New Haven companies in which we have strong, personal connections to the founders or investors or where we can add substantial value. INVESTING IN PEOPLE In making investment decisions, we weigh the strength of the team as much as the technology or markets being addressed – often more. We look for creative thinking, high intelligence, passion, and a deep commitment to working hard for success. Building great businesses takes time and hard work. THERE AT THE START We are interested in investing as early as a good idea comes together, or later, as the team is formed and the business develops. We have been co-founders of a number of our portfolio companies, and find that the most rewarding (and hardest) thing we do. We typically make first investments of $500,000 to $1 million, and, if a company is tracking well, look to invest an additional $2 to $2.5 million over multiple financing rounds. We are happy to syndicate with other investors who share our views and approach to investing.

Our Ventures team supports the launch of startups based on University of Michigan technologies and research discoveries. We provide a full suite of resources, services and funding to help you launch sustainable, impactful world changing startups. The Ventures team will engage with you from day one to establish clear and executable commercialization, business formation and funding strategies. As your startup project begins to take form we can provide grant funding and investment capital, as well as business know-how, talent resources and connections to a nationwide network of investors. Whether it is helping you find the perfect team member, investment partner or connecting you with service providers, we have you covered.

We are in the midst of technological shifts at a pace faster than ever before. Calculus VC capitalizes on these shifts to deliver returns and impact. We invest in the Series A and Series B stages of startups in the below sectors: FUTURE OF COMPUTING AND AI Continued advancements in AI will demand new developments in hardware and software. New computing materials and interfaces may emerge. Computing power may be more distributed, and the world will be infinitely more connected. These and more, are our areas of interest: Intelligence beyond language: We expect AI to understand quantitative models and physical phenomenon just as well as it understands language. Large Quantitiative Models are a focus for us. New hardware, materials, and architectures: We expect that demand for computing power will grow exponentially. Quantum computing, as well as distributed computing are expected to grow. We expect advancements in computing materials beyond silicon. Immersive and neural interfaces: These interfaces already exist, we expect they will become more mainstream. Spatial computing, integrating the physical world with digital environments may be our future. COMPUTATIONAL LIFE SCIENCES AND HEALTHTECH Breakthroughs in biology, materials, sensors, and data science are converging to redefine healthcare. Precision and personalization will take center stage as AI enhances how we detect, monitor, and treat disease. Areas of interest include: AI-First Therapeutics and Discovery Platforms: ML-powered platforms designing drugs and biologics via simulation, predictive modeling, and data-rich experimentation. Infrastructure for Programmable Biology: Tools that make biology engineerable – lab automation, bioinformatics, 3D bioprinting, next-gen diagnostics and R&D devices. Continuous, Data-Driven and Personalized Care: Wearables, medical devices, and diagnostics to deliver patient-centric care. These models turn users into real-time data streams, enabling adaptive treatment and personalized interventions. ADVANCED INDUSTRIAL TECHNOLOGIES As we expand the frontiers of possibility, we expect industry to evolve with intelligence, autonomy and environmental sustainability at its core. Areas of focus include: AI and automation in industry: Intelligent machines will optimize production, reduce waste, and enable new workflows. From predictive maintenance to robotic manufacturing, automation will power the next industrial revolution. We support startups enabling this vision. Land, ocean, and space transport and communications: We are interested in advanced materials, robotics, sensors, systems and software that will unlock new frontiers from deep-sea mapping to planetary missions. Resource efficiency: Building the future will demand large reserves of energy and natural resources. Technologies that can serve our energy, food, water, and agricultural needs while supporting a better planet are of interest to us.

InnoCom makes investments into worthy Life Science companies, providing: Investment opportunities in cutting edge technologies Access to early commercialization for life Science innovators Capital of $3 to 15 Million USD initial tranche for a company to complete its R&D, Preclinical & Phase I Trials; additional funding to complete Phase II Trials to take products to Licensing Industry networking to access revenue at 2-3 years following pre-clinical trials Providing revenue and/or takeout at 7 years end of clinical trials Business Counsel and advice to the company management team Corporate Officer participation, setting up strong Systems, Procedures, and Protocols Board of Directors Membership, building strong Corporate Governance Life Science Expertise, providing commercialization at the end of Preclinical and/or Clinical I & II Trials at 2-3 years Licensing Upfront Fees at 3 years, Revenue and/or Takeout at end of Clinical Trials at 7 years Enhancing the delivery of health solutions to the patients who need them